Prelude Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $10,443 - $12,220	-708 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $35,761 - $39,471	-2,144 Reduced 75.18%	708 $13,000
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $449,248 - $540,589	-26,630 Reduced 90.33%	2,852 $48,000
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $472,254 - $586,858	27,682 Added 1537.89%	29,482 $578,000
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $30,150 - $37,440	1,800	1,800 $36,000

488

122M

208K

66.3K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.29B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.